Vaxcyte, Inc.

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 11/09/2024 am IST			5-day change	1st Jan Change
116.23 ^USD	+0.82%		+5.52%	+85.08%

10/09	Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...
10/09	Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Vaxcyte, Inc.

Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...	10/09
Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	10/09	MT
Health Care Helped By Defensive Bias - Health Care Roundup	07/09	DJ
Vaxcyte Closes $1.5 Billion Offering of Shares, Warrants	07/09	MT
Vaxcyte Prices $1.3 Billion Offering of Shares, Warrants	05/09	MT
Health Care Losses Limited By Vaxcyte's Surge - Health Care Roundup	04/09	DJ
Vaxcyte Starts $1 Billion Underwritten Public Offering	04/09	MT
Sector Update: Health Care Stocks Decline Late Afternoon	04/09	MT
Sector Update: Health Care Stocks Retreat in Afternoon Trading	03/09	MT
Sector Update: Health Care	03/09	MT
Vaxcyte Shares Rise After Plans for Phase 3 Trial of 31-Valent Pneumococcal Conjugate Vaccine Candidate	03/09	MT
Vaxcyte's shares hit record high on early data on pneumococcal vaccine	03/09	RE
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	03/09	MT
Wall Street Set to Open Shortened Week Lower Tuesday as Investors Await Manufacturing Data	03/09	MT
Sector Update: Health Care	03/09	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Key Jobs Report	03/09	MT
Vaxcyte Plans Phase 3 Trial for 31-Valent Pneumococcal Conjugate Vaccine Candidate After 'Positive' Phase 1/2 Study Results	03/09	MT
September Kicks Off With US Futures Moving Lower Ahead of Manufacturing Data	03/09	MT
Transcript : Vaxcyte, Inc. - Special Call	03/09
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older	03/09	CI
Vaxcyte Insider Sold Shares Worth $1,184,767, According to a Recent SEC Filing	27/08	MT
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07/08	CI
Vaxcyte Insider Sold Shares Worth $1,263,912, According to a Recent SEC Filing	25/07	MT
Vaxcyte Insider Sold Shares Worth $649,325, According to a Recent SEC Filing	23/07	MT
Vaxcyte Insider Sold Shares Worth $425,000, According to a Recent SEC Filing	18/07	MT

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Employees

254

Sector

Biotechnology & Medical Research

Calendar

04/11/2024 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company